NSE: DRREDDY · 7 October 2026
- Dr. Reddy's Laboratories shares edged lower during the session, declining 0.35% to close at ₹1,203.80 after moving within a day's range of ₹1,192.40 and ₹1,222.50.
- The company disclosed that its step-down wholly owned subsidiary, Dr. Reddy's Laboratories, Inc., received a transcript from the US Internal Revenue Service classifying an amount of $32,350.20 as a penalty due to a fiscal year reference misclassification during tax payment. Management evaluated the order and confirmed there is no material impact on financials or operations.
- Trading volume was 0.83 times the 20-day average daily volume.
Why is Dr. Reddy S Laboratories share price falling on 7 October 2026?
Dr. Reddy's Laboratories shares edged lower during the session, declining 0.35% to close at ₹1,203.80 after moving within a day's range of ₹1,192.40 and ₹1,222.50.
The broader market experienced downward pressure, with the Nifty benchmark declining 0.76% and the Nifty Pharma sector index falling 0.43%. Dr. Reddy's movement remained broadly aligned with the defensive posture seen across pharmaceutical peers during the session.
Company disclosures showed that Dr. Reddy's recently issued an intimation on October 07, 2026, regarding its upcoming Q2FY27 financial results and earnings call scheduled for October 23, 2026. Additionally, a subsidiary recently received a minor tax misclassification penalty notice from the US Internal Revenue Service, though management noted no material financial impact.
17.33 lakh shares traded by 7 October 2026 · 03:15 PM IST. This compares with a 20-day average daily volume of 20.84 lakh shares (0.83 times). The five-day average daily volume was 22.70 lakh shares. Separately, the NSE report for 6 October 2026 showed 8.41 lakh shares delivered, representing 51.36% of that day’s traded volume. The same report recorded 40,801 trades.
The modest price decline of 0.35% occurred alongside a softer broader market and below-average cash volume participation. No single new operational catalyst occurred today to drive the move.
Latest Company Developments
The company disclosed that its step-down wholly owned subsidiary, Dr. Reddy's Laboratories, Inc., received a transcript from the US Internal Revenue Service classifying an amount of $32,350.20 as a penalty due to a fiscal year reference misclassification during tax payment. Management evaluated the order and confirmed there is no material impact on financials or operations.
Regulatory and tax notices require mandatory disclosure, though immaterial monetary penalties typically have a limited direct effect on corporate fundamentals.
Dr. Reddy's entered into an exclusive distribution and marketing agreement with Takeda Biopharmaceuticals India Private Limited for Qdenga®, India's first approved dengue vaccine, in the private market. The vaccine is anticipated to become available in the first half of 2027 following CDSCO approval for individuals aged 4 to 60 years.
This partnership strengthens the company's vaccine portfolio in India's private healthcare segment, supporting long-term growth vectors in preventive therapeutics.
imposition of penalty to Dr. Reddy s Laboratories, Inc. ( DRL Inc ), a step-down wholly owned subsidiary of the Company.
The exchange sought clarification from the company regarding a recent media report. Such a request is a verification step and does not by itself confirm the reported issue.
Dr. Reddy's Laboratories Limited has today, i.e., September 18, 2026, entered into an exclusive distribution and marketing agreement with Takeda Biopharmaceuticals India Private Limited for Qdenga® in the private market in India.
Ownership & Transaction Activity
Mutual Fund Holdings
Mutual funds held 13.16% on 30 June 2026. This compares with 13.19% on 31 March 2026, a change of -0.03 percentage points.
The filing reported 40 MF/UTI holders.
What to Watch Next
- Release of Q2FY27 financial results and management commentary scheduled for October 23, 2026
- Delivery volume trends against the 20-day average cash volume of 8,41,314 shares recorded on October 06
- Preparations for the commercial launch of the Qdenga dengue vaccine expected in the first half of 2027
- Performance relative to the Nifty Pharma sector benchmark
Other Dated Coverage
- Dr. Reddy's Shares Dip 0.27% Amid Pharma Sector Consolidation | 5 October 2026 — 5 October 2026
- Why Dr. Reddy's Shares Fell 2.75% Today | 1 October 2026 — 1 October 2026
- Why Dr. Reddy's Shares Fell 1.51% Today Amid Pharma Sector Weakness | 30 September 2026 — 30 September 2026
More Dr. Reddy S Laboratories news and dated analysis →
Frequently Asked Questions
What is the latest Dr. Reddy S Laboratories company news?
The company disclosed that its step-down wholly owned subsidiary, Dr. Reddy's Laboratories, Inc., received a transcript from the US Internal Revenue Service classifying an amount of $32,350.20 as a penalty due to a fiscal year reference misclassification during tax payment. Management evaluated the order and confirmed there is no material impact on financials or operations.
How strong was Dr. Reddy S Laboratories’s trading volume?
17.33 lakh shares traded, 0.83 times the 20-day average daily volume. The price and volume data are dated 7 October 2026 · 03:15 PM IST.
Do the mutual-fund figures show buying today?
They show holdings on 30 June 2026. Quarterly holdings do not identify purchases made on the article date.
Research & analysis: WittyTrades Research Desk
Reviewed by: Mohanish Sanghavi — SEBI Registered Research Analyst
Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.